Are United States and Canadian cancer screening rates consistent with guideline information regarding the age of screening initiation?

To understand whether US and Canadian breast, colorectal and prostate cancer screening test utilization is consistent with US and Canadian cancer screening guideline information with respect to the age of screening initiation. Cross-sectional, regression discontinuity. Canada and the US. Canadian and American women of ages 3060 and men of ages 4060. None. Mammography, prostate-specific antigen (PSA) and colorectal cancer test use within the past 2 years. We identify US and Canadian compliance with age screening information in a novel manner, by comparing test utilization rates of individuals who are immediately on either side of the guideline recommended initiation ages. US mammography utilization within the last 2 years increased from 33 at age 39 to 48 at age 40 and 60 at age 41. US colorectal cancer test utilization, within the last 2 years, increased from 15 at age 49 to 18 at age 50 and 28 at age 51. US PSA utilization within the last 2 years increased from 37 at age 49 to 44 at age 50 and 54 at age 51. In Canada, mammography utilization within the last 2 years increased from 47 at age 49 to 57 at age 50 and 66 at age 51. American and Canadian cancer screening utilization is generally consistent with each countrys guideline recommendations regarding age. US and Canadian differences in screening due to guidelines can potentially explain cross-country differences in breast cancer mortality and affect interpretation of international comparisons of cancer statistics.